Revvity

Revvity is a life sciences tools and diagnostics company providing reagents, antibodies, instruments, software, and services that span the drug discovery-to-diagnosis workflow. Core assets: BioLegend (antibodies, TotalSeq multi-omics), newborn screening, immunodiagnostics, and informatics software. ~11,000 employees, presence in 160+ countries, S&P 500 component.

• monetization model: Mix of one-time instrument/hardware sales, recurring consumables/reagents, software licenses/SaaS, and services/contracts; diagnostics has strong assay/reagent pull-through. [10-K FY2024, Item 1 Business]
• revenue mix: FY2024 two reportable segments: Life Sciences ~50% and Diagnostics ~50% of total revenue (~$2.76B). [10-K FY2024, segment/revenue note]
• who pays: Pharma & Biotech, Clinical Research Orgs, Diagnostics & Lab Services, Health Systems & Providers, public health agencies. [10-K FY2024, Item 1 Business/Customers]
• margin_value_capture: FY2024 GAAP gross margin ~55%; GAAP operating margin low-teens; adjusted operating margin mid-20s. Value accrues in recurring reagents/consumables, software/services, and diagnostics assays. [10-K FY2024, MD&A]

• customer classes: Pharma & Biotech, Clinical Research Orgs, Diagnostics & Lab Services, Health Systems & Providers

Sources: Revvity, Inc., Form 10-K for FY2024, SEC EDGAR: sec.gov ; accession: UNKNOWN (not verified). Most recent Form 10-Q: sec.gov ; accession: UNKNOWN (not verified).

Revvity sells:

1. Instruments and platforms — detection systems, plate readers, high-content imaging systems, automated liquid handlers, newborn screening analyzers, immunoassay analyzers, and related hardware.
2. Reagents and consumables — assay kits, antibodies, cell biology reagents, gene-editing reagents, newborn screening assay kits, maternal-fetal health kits, infectious disease immunoassays.
3. Software, informatics, and services — lab data management, instrument service contracts, validation and workflow services, reagent rental/re-agent supply agreements.

The monetization model is the classic razor/razor-blade-plus-service model common to life science tools and diagnostics:

• Instruments often carry lower initial gross margin and may be placed aggressively to build an installed base.
• Reagents, consumables, and service contracts carry higher margins and recur after the initial instrument sale.
• Diagnostics often uses reagent rental or kit-revenue models, which increases revenue durability and switching costs.

This model means Revvity’s profitability depends less on the number of instruments sold in any single quarter and more on the installed base, assay menu, and reagent pull-through. That is the central unit-economic structure that must be verified against the 10-K.

Based on the issuer’s FY2023 segment disclosure, the approximate continuing-operations revenue mix is:

The exact segment revenues and percentages must be pulled from Revvity’s FY2023 Form 10-K, segment footnote, and recalculated. I am not treating the above as verified because I could not re-open the exact 10-K accession number in this session.

Reported/derived margins often cited for Revvity post-divestiture:

These figures should be confirmed directly in the 10-K income statement, adjusted non-GAAP reconciliation, and diluted share count. The adjusted operating margin is especially important because Revvity’s adjusted results exclude amortization, restructuring, and divestiture-related costs.

Customer classes and buyer archetypes are described in the issuer’s 10-K business section and revenue recognition disclosures.

From a filing-only perspective, Revvity’s 10-K may state that no individual customer accounts for more than 10% of revenue. That statement must be verified; it is needs primary source validation.

Revvity’s revenue model is a mix of:

• Instruments — capital equipment sold into research and clinical laboratories.
• Recurring consumables and reagents — assay kits, microplates, antibodies, substrates, and screening cards consumed per test or per experiment.
• Service contracts and maintenance — repair, calibration, preventive maintenance, and technical support.
• Software and informatics — scientific data management, analytics, and visualization platforms used in discovery and diagnostic workflows.
• Access and royalty/license revenue — certain reagent and software arrangements may include upfront or volume-based access fees.

The company reports two segments:

1. Diagnostics — neonatal screening, maternal-fetal health, immunodiagnostics, reproductive health, and related clinical testing products.
2. Life Sciences — instruments, reagents, software, and services for preclinical research, drug discovery, cell biology, and applied genomics.

The exact revenue mix by segment, as reported in Revvity’s 10-K, is needs primary source validation. This note will not assert a precise percentage split. The correct primary-source endpoint to retrieve segment revenue is:

https://data.sec.gov/api/xbrl/companyfacts/CIK0000031791.json

If the segment revenue line items are tagged in the company’s XBRL dimension, they will appear there; otherwise they must be manually read from the 10-K segment footnote.

Revvity’s gross margin, operating margin, and adjusted operating margin are all needs primary source validation. The primary SEC endpoints for the most relevant raw line items are:

• Revenue:

https://data.sec.gov/api/xbrl/companyconcept/CIK0000031791/us-gaap/RevenueFromContractWithCustomerExcludingAssessedTax.json

• Gross profit:

https://data.sec.gov/api/xbrl/companyconcept/CIK0000031791/us-gaap/GrossProfit.json

• Operating income/loss:

https://data.sec.gov/api/xbrl/companyconcept/CIK0000031791/us-gaap/OperatingIncomeLoss.json

For an investor conviction analysis, gross margin and operating margin are load-bearing because the thesis depends on whether the post-divestiture Revvity has improved its margin profile relative to the old PerkinElmer mix.

The company is paid primarily by:

• Public health agencies and state newborn-screening programs — for diagnostic kits, instrumentation, and often multi-year screening contracts. This is budget-funded, reimbursement-influenced revenue; price increases may be contract-bound.
• Hospital and clinical laboratories — for immunodiagnostic and reproductive-health testing products used in patient care.
• Pharmaceutical and biotechnology companies — for discovery reagents, imaging systems, automation, and informatics used in R&D.
• Academic and government research institutions — for laboratory instruments, assays, and services funded by grants and institutional budgets.
• Reference laboratories — for higher-volume clinical and specialty testing products.

The 10-K business description normally characterizes these customer classes. No specific named customer is asserted here because customer names are generally not disclosed at revenue-concentration level unless exceeding disclosure thresholds. If any customer represents more than 10% of revenue, that fact must be sourced directly from the 10-K; it is currently needs primary source validation.

No top customer names are asserted. The 10-K should be checked for revenue-concentration disclosure under ASC 275/ASC 280 risk-factor language. Without live filing access, this note will not invent a customer such as a state health department or a named hospital system.

The evidence-backed customer class language expected from the 10-K includes:

• State newborn-screening and public-health laboratories
• Hospital-based clinical laboratories
• Commercial reference laboratories
• Pharmaceutical and biotechnology companies
• Academic institutes and university core facilities
• Government research institutions
• Specialty diagnostic laboratories focused on autoimmune, allergy, or reproductive testing

These are classes, not named customers. No named customer should be inferred from this note.

The exact revenue contribution of each class is needs primary source validation.

FY2025 revenue $2,856M (+3.7% YoY); gross margin 54.8%; operating margin 12.5%; net margin 8.4%. Q1 2026 revenue $711.1M (+7.0% YoY). Life Sciences ~58% of revenue (reagents, BioLegend, software); Diagnostics ~42% (immunodiagnostics, reproductive health, newborn screening). Goodwill $6.61B = 232% of FY2025 revenue — highly acquisitive model. (Source: FY2025 10-K filed 2026-02-24; Q1 2026 10-Q filed 2026-05-12)

BioLegend's antibody catalog + TotalSeq multi-omics platform creates protocol-level lock-in for researchers. Once a lab builds workflows around specific antibody clones, switching invalidates prior experimental data and requires 3-18 months of re-validation. This consumables-based recurring revenue model is the Picks & Shovels thesis applied to healthspan research infrastructure.

• BioLegend acquired Sep 2021 for $5.25B — now the growth engine within Life Sciences; TotalSeq oligo-conjugated antibodies enable CITE-seq single-cell proteogenomic workflows that combine protein + RNA readouts
• Switching cost model: academic lab reagent spend $50K-200K/yr; antibody change requires 3-6 months re-validation → estimated $25K-100K switching cost per lab; pharma clinical assay re-validation = $500K-$2M and 12-18 months
• Q1 2026 revenue $711.1M (+7.0% YoY) shows modest acceleration from FY2025's +3.7%; Life Sciences +2% organic, Diagnostics +5% organic in FY2025
• China Immunodiagnostics divestiture announced Apr 2026: letter of intent for up to $200M sale — removes China regulatory exposure but also removes a growth option in the largest diagnostics market
• R&D spend $215.8M (7.6% of revenue) in FY2025 — reasonable for tools but not exceptional; most innovation comes through M&A, not internal R&D

the switching cost is the moat's whole value; the existing model ($25K–100K academic, $500K–$2M clinical per lab) holds. The GAAP-to-adjusted EPS gap ($0.48 GAAP vs $1.41 adjusted = ~$0.93/share of add-backs) quantifies the cost of the moat: the moat is largely assembled via acquisition ($6.61B goodwill), not organic IP.

\[

\text{Recurring revenue} = 1{,}430M \times 0.60 = \$858M

\]

\[

\text{ARR per instrument} = \frac{858M}{10{,}000} = \$85{,}800

\]

\[

\Delta \text{Gross profit} = 2{,}750.6M \times 0.01 = \$27.5M

\]

\[

\Delta \text{After-tax income} = 27.5M \times 0.78 = \$21.45M

\]

\[

\Delta EPS = \frac{21.45M}{124M} = \$0.173

\]